


2016 PROGRAM BOOK



President Thomas A. Gardner, MD welcomes you to the IUA 2016 Annual Meeting.

IUA Board of Directors 2015 – 2016

President

Thomas A. Gardner, MD

President-Elect

Kenneth G. Ney, MD

Secretary/Treasurer

Ronald S. Suh, MD

Immediate Past-President

Teresa D. Beam, MD, FACS

Members-at-Large

Bradley G. Orris, MD
Charles R. Powell II, MD
David H. Rosenbaum, MD

North Central Section Representative

Mark D. Dabagia, MD

President of the IUA NP/PA Association

Tracy Mullin, FNP, BC

2016 Program Planning Committee

Thomas A. Gardner, MD

Executive Director

Donna Rostamian, MBA

Associate Director

Samantha Panicola

IUA Executive Office

Two Woodfield Lake
1100 E. Woodfield Road, Suite 350
Schaumburg, Illinois 60173
Phone: (847) 517-7225
Fax: (847) 517-7229
info@iuaweb.org
www.iuaweb.org

Past Presidents

2014 – 2015	Teresa Beam, MD, FACS
2012 – 2013	Mark D. Dabagia, MD
2010 – 2011	Chandru P. Sundaram, MD
2008 – 2009	Samuel T. Thompson, MD
2005 – 2007	Christopher P. Steidle, MD



Indiana Urologic Association
2016 Annual Meeting
February 27, 2016

2015 - 2016 Board of Directors	Inside Cover
Educational Needs & Objectives	Page 3
CME Accreditation Statement.....	Page 3
Disclosure Report.....	Page 4
Promotional Partners & Exhibitors.....	Page 5
Industry Satellite Symposium Event.....	Page 6
General Meeting Information.....	Page 6
Scientific Program	Page 7
Speaker Biographies	Page 9
Notes	Page 11

Educational Needs

AUA Guidelines are constructed for a variety of urologic conditions through a thoroughly vetted process. These guidelines help urologists with the daily practice of caring for the urologic patient. It is critical for the practicing urologist or practitioner to understand the process and the implication of the AUA Guidelines and how to incorporate these into their practices.

With the advent of the Affordable Care Act and continued changes in health care coverage and regulation, health care policy continues to play a very important role in our medical practices. There is a need to be informed of health policy changes looming at the state, regional and national levels.

Social media continues to intrude on the physician-patient relationship. Understanding the different forms of social media and implications will benefit urologists especially in light of HIPPA requirements and caring for patients. It is important for urologists to understand the potential role of Twitter, Facebook, ResearchGate, Doximity, LinkedIn, etc.

Challenging cases in urology are every day experiences. The group analysis of these difficult cases allows the practicing urologist or practitioner to hone their skills in diagnosis and treatment options. Discussing these cases in a forum of experts and peers in the field of urology maximize the benefit of the presentation and discussions.

High Intensity Focused Ultrasound (HIFU) has recently been approved for the treatment ablation of prostate tissue. Understanding HIFU and its future role among the variety of treatments available for localized and recurrent prostate cancer is important information for urologists.

Utilizing mesh in the female genitourinary system can be quite complicated. Understanding the variety of complications that can occur and the treatments that are required to fix these complications is very important. These mesh complications can be extremely challenging to treat and often requires a multi-modality approach. A need exists for general urologists to understand these diagnosis and its treatments.

Educational Objectives

At the conclusion of the IUA 2016 Annual Meeting, attendees should be able to:

1. Describe the concept and usefulness of AUA Guidelines and how to use them in care of the urologic patient.
2. Describe the health policy issues facing urologists in Indiana, the North Central Section region and nationwide.
3. Describe the impact of social media on the practice of urology and understand the implications and HIPPA requirements associated with social media.
4. Describe and understand the role HIFU may play in the treatment of prostate cancer.
5. Evaluate and understand the treatment approaches and uses of mesh in the female genitourinary system.

CONTINUING MEDICAL EDUCATION CREDIT INFORMATION**Accreditation**

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Surgeons and the Indiana Urologic Association, Inc. The American College of Surgeons is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™

The American College of Surgeons designates this live activity for a maximum of **5.00 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



100+years

AMERICAN COLLEGE OF SURGEONS

Inspiring Quality:
Highest Standards, Better OutcomesAMERICAN COLLEGE OF SURGEONS
DIVISION OF EDUCATIONAccredited with Commendation by the
Accreditation Council for Continuing Medical Education

Nurses and other healthcare professionals will receive a Certificate of Attendance. For information on the applicability and acceptance of Certificates of Attendance for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by the ACCME, please consult your professional licensing board.

General Disclaimer

The statements and opinions contained in this program are solely those of the individual authors and contributors and not of the Indiana Urologic Association, Inc. The appearance of the advertisements is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. The content of this publication may contain discussion of off-label uses of some of the agents mentioned. Please consult the prescribing information for full disclosure of approved uses. The Indiana Urologic Association, Inc. disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the abstracts or advertisements.

Special Assistance

We encourage participation by all individuals. If you have a disability, advance notification of any special needs will help us better serve you. Call (847) 517-7225, if you require special assistance to fully participate in the meeting.

FACULTY DISCLOSURE REPORT

2016 IUA Annual Meeting

February 27, 2016

Indianapolis, Indiana

In accordance with the ACCME Accreditation Criteria, the American College of Surgeons, as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. Therefore, it is mandatory that both the program planning committee and speakers complete disclosure forms. Members of the program committee were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations. The ACCME defines a 'commercial interest' as "any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients". It does not consider providers of clinical service directly to patients to be commercial interests. The ACCME considers "relevant" financial relationships as financial transactions (in any amount) that may create a conflict of interest and occur within the 12 months preceding the time that the individual is being asked to assume a role controlling content of the educational activity.

ACS is also required, through our joint providership partners, to manage any reported conflict and eliminate the potential for bias during the activity. All program committee members and speakers were contacted and the conflicts listed below have been managed to our satisfaction. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage.

The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure and to allow the audience to form its own judgments regarding the presentation.

PLANNING COMMITTEE / CME ORGANIZERS	DISCLOSURE		
	Company	Role	Received
GARDNER, MD, Thomas CME Organizer	Nothing to disclose		
SPEAKERS / MODERATORS / PANELISTS / DISCUSSANTS / CO-AUTHORS	DISCLOSURE		
	Company	Role	Received
BAHLER, MD, MS, Clinton Speaker	Nothing to disclose		
COOKSON, MD, MMHC, Michael Speaker	Astellas	Advisory Board	Honorarium
	Bayer Health Care Pharmaceuticals	Advisory Board	Honorarium
	MDxHealth	Advisory Board	Honorarium
HEINSIMER, MD, Kevin Speaker	Nothing to disclose		
HOLLENBECK, MD, MS, Brent Speaker	Nothing to disclose		
JAQUA, MD, Kaitlin Speaker	Nothing to disclose		
KOCH, MD, Michael Speaker	Nothing to disclose		
LARGE, MD, MA, Tim Speaker	Nothing to disclose		
MULLINS, MD, Ryan Speaker	Nothing to disclose		
ORRIS, MD, Bradley Speaker	Nothing to disclose		
POWELL, MD, Charles Speaker	Nothing to disclose		
TATEM, MD, Alexander Speaker	Nothing to disclose		

Thank You to Our 2016 Promotional Partner

(Alphabetical as of 2/1/2016)

Platinum Level

Endo Pharmaceuticals

Thank You to Our 2016 Exhibitors

(Alphabetical as of 2/1/2016)

AbbVie
Allergan
Astellas Oncology
Astellas Pharma US, Inc.
Bayer HealthCare
BK Ultrasound
Boston Scientific Corporation
Coloplast
Cook Medical
Endo Pharmaceuticals
Ferring Pharmaceuticals
GenomeDx Biosciences Inc.
Janssen Biotech
KARL STORZ
MDxHealth
NeoTract, Inc.
Olympus America Inc.
Retrophin
Richard Wolf Medical Instruments, Corp.
sanofi Oncology
TOLMAR Pharmaceuticals

Saturday, February 27, 2016

11:30 a.m. – 12:30 p.m.

Industry Satellite Symposium Luncheon

Location: Circle Suites

“Peyronie’s Disease and an Overview of Xiaflex”

Speaker: Andrew McCullough, MD
The Urological Institute of Northeastern New York
Albany, New York

***DISCLAIMER**

In order to be in compliance with the PhRMA Code on Interactions with Healthcare Professionals and other regulations and policies, attendance to this event is limited to healthcare professionals (HCPs) only. Accordingly, attendance by guests or spouses is not permitted. This event will include the provision of modest food and beverages. Endo Pharmaceuticals Inc. does not intend to offer such provisions to HCPs whose institutions prohibit such offerings, nor does Endo offer food or beverages where federal or state laws (eg, Minnesota and Vermont) limit an HCP’s ability to accept food or beverages. Accordingly, please consult your legal or ethics advisor regarding any applicable limitation before attending this event. By attending this event, you represent that it is permissible for you to accept food and beverages under these laws or policies. Please note that Endo is required to report the value of food and beverages provided pursuant to applicable federal and/or state laws.

General Meeting Information

Registration/Information Desk Hours

Location: Meridian West Lobby

Saturday, February 27, 2016 6:30 a.m. – 3:30 p.m.

Exhibit Hall Hours

Location: Meridian Center

Saturday, February 27, 2016 7:00 a.m. – 2:00 p.m.

Registration Fee Includes:

- Entrance to Scientific Sessions
- Breakfast/Breaks/Lunch
- Program Materials

Course Description

The IUA provides a quality support system for the urology physicians in Indiana, and those practicing this specialty in surrounding environs adjacent to the state of Indiana, in the efforts to better serve patients, people and the community areas. The 2016 scientific program will offer presentations on topics of interest to urologists including AUA guideline updates, Indiana health policy updates, health policy reforms and their implications on urologic diseases, social media within urology, the impact of FDA approval of HIFU for prostate cancer, examining evidence from literature for and against vaginal mesh use, and more.

All sessions will be located in **Meridian West** unless otherwise noted.
Speakers/times are subject to change

SATURDAY, FEBRUARY 27, 2016

OVERVIEW

6:30 a.m. - 3:30 p.m. **Registration/Information Desk Open**
Location: Meridian West Lobby

7:00 a.m. - 2:00 p.m. **Exhibit Hall Open**
Location: Meridian Center

7:00 a.m. - 8:00 a.m. **Continental Breakfast in Exhibit Hall**
Location: Meridian Center

GENERAL SESSION

7:45 a.m. - 8:00 a.m. **Annual Business Meeting**

8:00 a.m. - 8:05 a.m. **Welcome**
President: Thomas A. Gardner, MD
Indiana University Medical Center

8:05 a.m. - 9:05 a.m. **AUA Guidelines Update**
Guest Speaker: Michael S. Cookson, MD, MMHC
University of Oklahoma Health Sciences Center

9:05 a.m. - 9:50 a.m. **Resident Case Presentations**
Judges: Michael S. Cookson, MD, MMHC
University of Oklahoma Health Sciences Center
Brent K. Hollenbeck, MD
University of Michigan

Transgluteal Computerized Tomography-Guided Percutaneous Renal Access for Percutaneous Nephrolithotomy in a Pelvic Horseshoe Kidney

Presenter: Ryan J. Mullins, MD
Indiana University

Kid's Questionable Kidney

Presenter: Kevin R. Heinsimer, MD
Indiana University

Mass-ively Overweight

Presenter: Kaitlin R. Jaqua, MD
Indiana University

What's that Growing in my Testicle

Presenter: Tim Large, MD, MA
Indiana University

The Case of the Purple Scarf

Presenter: Alexander Tatem, MD
Indiana University

9:50 a.m. - 10:35 a.m. **Break and Networking in Exhibit Hall**
Location: Meridian Center

10:35 a.m. - 10:55 a.m. **Indiana Health Policy Update**
Speaker: Bradley G. Orris, MD
Urology of Indiana

10:55 a.m. - 11:30 a.m. **Social Media and Your Cyber Identity: What is your Twitter Handle?**
Speaker: Clinton D. Bahler, MD, MS
Indiana University

11:30 a.m. - 12:30 p.m. **Industry Satellite Symposium Luncheon**
Location: Circle Suites

12:30 p.m. - 1:20 p.m. **Impact of FDA Approval of HIFU for Prostate Cancer**
Speaker: Michael O. Koch, MD
Indiana University Medical Center



Clinton D. Bahler, MD, MS

Dr. Bahler completed medical school at Indiana University after finishing a degree in biomedical engineering at Purdue University with highest distinction. He completed his urologic surgery residency at Indiana University, and chose to undergo additional specialty fellowship training in laparoscopic and robotic surgery with Dr. Chandru Sundaram at Indiana University. His areas of interest are urologic cancers including kidney, prostate, and adrenal and benign urologic diseases including urinary obstruction and stone disease.



Michael S. Cookson, MD

Dr. Cookson is professor and chairman of the department of urology at the University of Oklahoma Health Sciences Center, and holds the Donald D. Albers Endowed Chair in Urology. An accomplished researcher and lecturer, he is the author of 206 peer-reviewed journal publications and 28 chapters of various textbooks in urology and urologic surgery, and has been recognized nationally for his outstanding contributions to urologic oncology.

Dr. Cookson completed his urology residency at the University of Texas, San Antonio and completed his Urologic Oncology Fellowship at Memorial Sloan-Kettering Cancer Center in New York. He was a member of the faculty at Vanderbilt University from 1998 to 2013, where he served as the vice chairman of urologic surgery and director of the Urologic Oncology Fellowship Program.

Dr. Cookson has devoted a significant portion of his academic career to the management of patients with urologic cancers, with a strong emphasis on Clinical Guidelines, Education and Evidenced Based Medicine. He was a member of the AUA/ABU examination committee for 10 years, including a member of Task for Cancer, Oncology Consultant and Pathology editor. He also serves on the ABU Oral Examination Committee. He is a co-founder of the OKAT, an SUO mandated oncology examination that is the standard for benchmarking for members and oncology fellows in training and served as Chair of that OKAT committee for five years. In 2011, he received the President's Distinguished Service Award from the SUO for educational contributions. For his efforts in teaching at Vanderbilt, he was awarded the Michael Rodriguez Award.

Dr. Cookson recently served as the Chair of the AUA Guidelines Committee on Castration Resistant Prostate Cancer, and has previously served as the member of the AUA Guidelines on localized prostate cancer. He currently serves as Treasurer for the Society of Urologic Oncology.



Thomas A. Gardner, MD

Dr. Gardner has devoted his entire career to the clinical, research and educational advancement of the profession of urology. After completing his residency at New York Hospital and AFUD Fellowship at the University of Virginia, Dr. Gardner worked as a physician-scientist at Indiana University Medical Center. He continued on to Indiana University to develop a research program and build a practice in urologic oncology, where he successfully secured funding to establish a basic and translation research program from 1999 to 2009. He then transitioned his research efforts to clinical trials and has directed a successful clinical trial program. Dr. Gardner moved on to director of clinical trials within the program.

Dr. Gardner specializes in the care of patients with cancers of the urinary tract including prostate, kidney and bladder. He joined the Indiana University faculty after completing an American Foundation of Urologic Diseases Fellowship in Gene Therapy for Prostate and Kidney Cancer at the University of Virginia. He continues to develop novel therapies for patients with urologic cancers and conducts clinical trials through the IU Cancer Center.

He is a participant with AUA and NCS, in addition to continued involvement with abstracts, presentations and a multitude of activities with meetings.

**Brent K. Hollenbeck, MD, MS**

Dr. Hollenbeck is a practicing urologic oncologist and has been on faculty at the University of Michigan since 2003. A graduate of the Indiana University School of Medicine, Dr. Hollenbeck completed his residency in urology and fellowship training in oncology at the University of Michigan. He has a busy oncology practice that is specialized in caring for patients with prostate cancer.

During his fellowship training, Dr. Hollenbeck completed a Masters of Science program in research design and biostatistics at the University of Michigan's School of Public Health. His research interests are policy-oriented and are focused squarely on understanding the upstream influences and downstream consequences of variation in physician practice style. In particular, his work is seeking to understand the implications of financial incentives for the healthcare delivery system. His work is funded by four large extramural grants from the NIA, NCI, AHRQ and the American Cancer Society.

Dr. Hollenbeck is currently a professor of urology and the associate chair for research at the University of Michigan. He is firmly committed to training the future leaders in urologic health services research. Further, he strongly believes that populating the surgical specialties with health services researchers will yield long-term benefits to both our specialty and our patients.

**Michael O. Koch, MD**

Dr. Koch has been a chairman and professor of urology at Indiana University School of Medicine since 1998. His clinical practice is in urologic oncology with a focus in prostate and bladder cancer. Dr. Koch and his colleagues were the investigators of the first trial in the United States on the use of high intensity focused ultrasound for the treatment of prostate cancer and have previously conducted trials on whole gland therapy and salvage protocols after radiation failure. He and his colleagues believe that the future of prostate cancer care will have a select role for partial gland ablation with new technologies.

**Bradley G. Orris, MD**

Dr. Orris is a native of Indianapolis and active with state and national medical advocacy. He is a graduate of Purdue University in West Lafayette, Indiana, where he received his BS in Electrical Engineering with a biomedical emphasis. He earned his medical degree from the Indiana University School of Medicine, Indianapolis, and completed his general surgery residency and urology residency at Loyola University Medical Center in Chicago, Illinois. He enjoys traveling, jogging and golfing. He is married and has three children.

**Charles R. Powell, II, MD**

Dr. Powell is an associate professor of urology at the Indiana University School of Medicine who specializes in female pelvic medicine and reconstructive surgery (FPMRS), including urethroplasty in males and females, robotic surgery for complex pelvic prolapse, neurogenic bladder and urinary diversion, and correction of complications from vaginal mesh. He completed a fellowship under Karl Kreder, MD at the University of Iowa after completing residency at the University of Illinois at Chicago, medical school at Indiana University, and electrical engineering at Purdue University.

In addition, he cares for patients with pelvic pain, including interstitial cystitis/bladder pain syndrome, urinary incontinence, urinary retention, botox, and sacral neuromodulation for overactive bladder (OAB). His research interests include development of wireless implantable devices for measuring bladder pressure, diabetes and its effects on the bladder, and female urethra reconstruction. He has been active in training residents not only in Indiana but also in Kenya and Gabon, and has an interest in missionary medicine.

SAVE THE DATES!



AUA 2016 Annual Meeting
May 6 - 10, 2016
San Diego Convention Center
San Diego, California

North Central Section of the AUA
90th Annual Meeting
September 7 – 10, 2016
Fairmont Chicago
Chicago, Illinois



Indiana Urologic Association
Two Woodfield Lake
1100 E Woodfield Road, Suite 350
Schaumburg, IL 60173
Phone: (847) 517-7225
Fax: (847) 517-7229
info@iuaweb.org
www.iuaweb.org